Journal Mobile Options
Table of Contents
Vol. 129, No. 2, 2002
Issue release date: October 2002
Int Arch Allergy Immunol 2002;129:108–112

Petasins in the Treatment of Allergic Diseases: Results of Preclinical and Clinical Studies

Thomet O.A.R. · Simon H.-U.
aDepartment of Pharmacology, University of Bern, and bDepartment of Medicine, GlaxoSmithKline, Münchenbuchsee, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Plant extracts are causing an increased interest in the treatment of many chronic diseases, including asthma and other allergic diseases. Several laboratories characterized petasins (petasin, isopetasin, and neopetasin) isolated from extracts of butterbur (Petasites hybridus) as pharmacologically active components, which inhibit leukotriene synthesis in leukocytes. The molecular mechanisms by which petasins abrogate inflammatory effector cell functions have, at least partially, been identified. In vitro studies revealed that petasins may have several intracellular targets and this may depend on the stereoisomer used. In an open clinical trial in patients suffering from allergic rhinitis, a reduction of leukotriene and histamine levels in nasal fluids was associated with the butterbur extract administration. To better evaluate the clinical value in this particular allergic disease, the clinical efficacy of the drug was compared with an established antihistamine treatment scheme in a double-blind study; no significant difference was observed between the two treatment groups. In this article, we critically review recently published work and summarize the current stage in the pharmacological characterization of butterbur extracts.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Parikh A, Scadding GK: Seasonal allergic rhinitis. BMJ 1997;314:1392–1395.
  2. Bousquet J, Duchateau J, Pignat JC, Fayol C, Marquis P, Mariz S, Ware JE, Valentin B, Burtin B: Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309–316.
  3. Juniper EF: Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S742–S749.
  4. Klimek L, Wolf H, Mewes T, Dormann D, Reske-Kunz A, Schnitker J, Mann W: The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999;103:47–53.
  5. Togias AG, Naclerio RM, Peters SP, Nimmagadda I, Proud D, Kagey-Sobotka A, Adkinson NF, Norman PS, Lichtenstein LM: Local generation of sulfidopeptide leukotrienes upon nasal provocation with cold, dry air. Am Rev Respir Dis 1986;133:1133–1137.
  6. Knapp HR: Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745–1748.
  7. Palmblad J, Lerner R, Larsson SH: Signal transduction mechanisms for leukotriene B4 induced hyperadhesiveness of endothelial cells for neutrophils. J Immunol 1994;152:262–269.
  8. Crooks SW, Bayley DL, Hill SL, Stockley RA: Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: The role of leukotriene B4. Eur Respir J 2000;15:274–280.
  9. Di Lorenzo G, Mansueto P, Melluso M, Candore G, Colombo A, Pellitteri ME, Drago A, Potestio M, Caruso C: Allergic rhinitis to grass pollen: Measurement of inflammatory mediators of mast cell and eosinophils in native nasal fluid lavage and in serum out of and during pollen season. J Allergy Clin Immunol 1997;100:832–837.
  10. Radmark O, Shimizu T, Jornvall H, Samuelsson B: Leukotriene A4 hydrolase in human leukocytes. Purification and properties. J Biol Chem 1984;259:12339–12345.
  11. Weller PF, Lee CW, Foster DW, Corey EJ, Austen KF, Lewis RA: Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: Predominant production of leukotriene C4. Proc Natl Acad Sci USA 1983;80:7626–7630.
  12. Glaser KB, Sung A, Bauer J, Weichman BM: Regulation of eicosanoid biosynthesis in the macrophage. Involvement of protein tyrosine phosphorylation and modulation by selective protein tyrosine kinase inhibitors. Biochem Pharmacol 1993;45:711–721.
  13. Lewis RA, Austen KF, Soberman RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645–655.
  14. Simon HU, Weber M, Becker E, Zilberman Y, Blaser K, Levi-Schaffer F: Eosinophils maintain their capacity to signal and release eosinophil cationic protein upon repetitive stimulation with the same ligand. J Immunol 2000;165:4069–4075.
  15. Rothenberg ME, Owen WFJ, Silberstein DS, Soberman RJ, Austen KF, Stevens RL: Eosinophils cocultured with endothelial cells have increased survival and functional properties. Science 1987;237:645–647.
  16. Takafuji S, Bischoff SC, De Weck AL, Dahinden CA: IL-3 and IL-5 prime normal human eosinophils to produce leukotriene C4 in response to soluble agonists. J Immunol 1991;147:3855–3861.
  17. Dahinden CA, Zingg J, Maly FE, De Weck AL: Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5A and FMLP as second signals. J Exp Med 1988;167:1281–1295.
  18. Bischoff SC, De Weck AL, Dahinden CA: Interleukin 3 and granulocyte/macrophage colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a. Proc Natl Acad Sci USA 1990;87:6813–6817.
  19. Brock TG, McNish RW, Coffey MJ, Ojo TC, Phare SM, Peters-Golden M: Effects of granulocyte-macrophage colony-stimulating factor on eicosanoid production by mononuclear phagocytes. J Immunol 1996;156:2522–2527.
  20. DiPersio JF, Billing P, Williams R, Gasson JC: Human granulocyte-macrophage colony-stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotriene B4 synthesis. J Immunol 1988;140:4315–4322.
  21. Zhu X, Birnbaumer L: G protein subunits and the stimulation of phospholipase C by Gs- and Gi-coupled receptors: Lack of receptor selectivity of Galpha(16) and evidence for a synergic interaction between Gbeta gamma and the alpha subunit of a receptor activated G protein. Proc Natl Acad Sci USA 1996;93:2827–2831.
  22. Clark JD, Lin LL, Kriz RW, Ramesha CS, Sultzman LA, Lin AY, Milona N, Knopf JL: A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 1991;65:1043–1051.
  23. Gijon MA, Leslie CC: Regulation of arachidonic acid release and cytosolic phospholipase A2 activation. J Leukoc Biol 1999;65:330–336.
  24. Rouzer CA, Kargman S: Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J Biol Chem 1988;263:10980–10988.
  25. Cowburn AS, Holgate ST, Sampson AP: IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. J Immunol 1999;163:456–465.
  26. Debrunner B, Meier B: Petasites hybridus: A tool for interdisciplinary research in phytotherapy. Pharm Acta Helv 1998;72:359–362.
  27. Lin YL, Mei CH, Hung SL, Kuo YH: Four new sesquiterpenes from Petasites formosanus. J Nat Prod 1998;61:887–890.
  28. Scheidegger C, Dahinden C, Wiesmann U: Effects of extracts and of individual components from petasites on prostaglandin synthesis in cultured skin fibroblasts and on leucotriene synthesis in isolated human peripheral leucocytes. Pharm Acta Helv 1998;72:376–378.
  29. Berger D, Burkard W, Schaffner W: Influence of Petasites hybridus on dopamine-D2 and histamine-H1 receptors. Pharm Acta Helv 1998;72:373–375.
  30. Thomet OAR, Wiesmann UN, Schapowal A, Blaser K, Simon HU: Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus. Biochem Pharmacol 2001;61:1041–1047.
  31. Thomet OAR, Wiesmann UN, Blaser K, Simon HU: Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in eosinophils. Clin Exp Allergy 2001;31:1310–1320.
  32. Ziolo G, Samochowiec L: Study on clinical properties and mechanisms of action of petasites in bronchial asthma and chronic obstructive bronchitis. Pharm Acta Helv 1998;72:378–379.
  33. Schapowal A on behalf of Petasites Study Group: Randomised controlled trial of butterbur and ceterizine for treating seasonal allergic rhinitis. BMJ 2002;324:144–146.
  34. Thomet OAR, Schapowal A, Heinisch IVWM, Wiesmann UN, Simon HU: Anti-inflammatory activity of an extract of Petasites hybridus in allergic rhinitis. Int Immunopharmacol 2002;2:997–1006.
  35. Bucher K: Über ein antispastisches Prinzip in Petasites officinalis Mönch. Arch Exp Pathol Pharmakol 1951;213:69–71.
  36. Ko WC, Lei CB, Lin YL, Chen CF: Relaxant effects of petasins in isolated guinea pig trachea and their structure-activity relationships. Planta Med 2000;66:650–652.
  37. Brune K, Bickel D, Peskar BA: Gastro-protective effects by extracts of Petasites hybridus: The role of inhibition of peptido-leukotriene synthesis. Planta Med 1993;59:494–496.
  38. Bickel D, Röder T, Bestman HJ, Brune K: Identification and characterization of inhibitors of peptido-leukotriene synthesis from Petasites hybridus. Planta Med 1994;60:318–322.
  39. Ko WC, Lei CB, Lin YL, Chen CF: Mechanisms of relaxant action of s-petasin and s-isopetasin, sesquiterpenes of Petasites formosanus, in isolated guinea pig trachea. Planta Med 2001;67:224–229.
  40. Wang GJ, Shum AY, Lin YL, Liao JF, Wu XC, Ren J, Cen CF: Calcium channel blockade in vascular smooth muscle cells: Major hypotensive mechanism of s-petasin, a hypotensive sesquiterpene from Petasites formosanus. J Pharmacol Exp Ther 2001;297:240–246.
  41. Oehling AG, Akdis CA, Schapowal A, Blaser K, Schmitz M, Simon HU: Suppression of the immune system by oral glucocorticoid therapy in bronchial asthma. Allergy 1997;52:144–154.
  42. Simon HU, Plötz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999;341:1112–1120.
  43. Gratzl S, Palca A, Schmitz M, Simon HU: Treatment with IFN-α in corticosteroid-unresponsive asthma. J Allergy Clin Immunol 2000;105:1035–1036.
  44. Mueller O, Villiger B, O’Callaghan B, Simon HU: Immunological effects of competitive versus recreational sports in cross-country skiing. Int J Sports Med 2001;22:52–59.
  45. Donnelly AL, Glass M, Minkwitz MC, Casale TB: The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734–1739.
  46. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wie LX: Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:917–922.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50